Skip to main content

Advertisement

SpringerLink
Log in

Nieuwe middelen in de behandeling van type 2 diabetes mellitus:

de sodium glucose transporter – 2 (SGLT2) remmer

  • Educatie
  • Published:
Nederlands Tijdschrift voor Diabetologie Aims and scope

Samenvatting

Dapagliflozine is de eerste uit een nieuwe klasse glucose verlagende medicijnen die binnenkort op de markt zullen komen. Het is een sodium-glucose transporter 2 (SGLT2) remmer waarbij het primaire gevolg verhoging van de renale glucose excretie is. Uit fase 3 onderzoek blijkt een HbA1c daling van 0.6-0.8%, een gewichtsreductie van 2-3 kilo in 24 weken en een daling van bloeddruk. De bijwerkingen ten gevolge van verhoogde glucosurie (toename van urineweg- en urogenitale infecties) bleken in deze studies gering en niet ernstig. De positie die dapagliflozine moet gaan innemen in het spectrum van de behandeling van diabetes nog niet duidelijk.

Summary

Dapagliflozin is the first of a new class of glucose lowering drugs that will be available for the treatment of diabetes mellitus. Dapagliflozin selectively inhibits renal glucose reabsorption by inhibiting sodium-glucose cotransporter-2 (SGLT2). It results in a decrease in HbA1c of 0.6-0.8%, a weight reduction of 2-3 kilo in 24 weeks and a decrease in blood pressure. Adverse events (mainly urinary tract infections and genital infections) were mild. The position of dapagliflozin as treatment for patients with type 2 diabetes mellitus remains to be established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figuur 1

Referenties

  1. Rutten GEHM, De Grauw WJC, Nijpels G, Goudswaard AN, Uitewaal PJM, Van der Does FEE Heine RJ, Van Ballegooie E, Verduijn MM, Bouma M. NHG standard diabetes mellitus type 2. Huisarts en Wetenschap 2006; 49: 137–152.

    Google Scholar 

  2. Woodcock J, Sharfstein J M and Hamburg M. Regulatory action on rosiglitazone by the US Food and Drug Administration. N Engl J Med 2010; DOI:10.1056/ NEJMp1010788.

  3. European Medicines Agency. European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone. Available from http://www.emea.europe.eu/pdfs/human/press/pr/48427707eu.pdf

  4. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 31: Suppl 1: S12- S54.

    Google Scholar 

  5. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozine, a novel SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes. Clin Pharmacol Ther 2009;85:513–519.

    Article  CAS  PubMed  Google Scholar 

  6. List JF, Woo V, Morales E. Sodium-glucose cotransport inhibition with dapagliflozine in type 2 diabetes. Diabetes Care 2009; 32: 650–7

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. SGLT2 inhibitors: Glucuretic treatment for type 2 diabetes. www.medscape.com

  8. Ehrenkranz JR, Lewis NG, Kahn CR. Phlorizin: a review. Diabetes Metab Rev 2005; 21: 31–38.

    Article  CAS  Google Scholar 

  9. Fujimori Y, Katsuno K, Ojima K et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009;609:148–54

    Article  CAS  PubMed  Google Scholar 

  10. Ferranini E, Ramos SJ, Salsali A. Dapafliglozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care in press

  11. Bailey CJ, Gross JL, Bastone L. Dapagliflozine as add-on to metformin lowers hyperglycemia in type 2 diabetes patients inadequately controlled with metformin alone. Lancet 2010; 375: 2223–2233.

    Article  CAS  PubMed  Google Scholar 

  12. Wilding JPH, Norwood P, Tjoen C. A study of dapagliflozine in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes care 2009; 32: 1656–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Wing RR, Hill JO. Succesful weight loss maintenance. Ann Rev Nutrution 2001; 323–341.

Download references

Author information

Authors and Affiliations

  1. Afdeling interne Geneeskunde, Twenteborg Ziekenhuis, 7600, Almelo, SZ, The Netherlands

    Th.F. Veneman

Authors
  1. Th.F. Veneman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Th.F. Veneman.

Additional information

1 Afdeling interne Geneeskunde, Twenteborg Ziekenhuis Almelo

Correspondentie:

Dr. Th.F. Veneman, internist-intensivist-diabetoloog, Twenteborg Ziekenhuis, Afdeling Interne Geneeskunde, Postbus 7600, 7600 SZ Almelo.

E-mail: tfveneman@hetnet.nl

Conflict of Interest:

Dr. Th. F. Veneman is lid van de nationale adviesraad van Astra Zeneca.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Veneman, T. Nieuwe middelen in de behandeling van type 2 diabetes mellitus:. NED. TIJDSCHR. DIABET. 9, 13–17 (2011). https://doi.org/10.1007/s12467-011-0003-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12467-011-0003-x

Search

Navigation